Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Schumacher, D; Andrieux, G; Boehnke, K; Keil, M; Silvestri, A; Silvestrov, M; Keilholz, U; Haybaeck, J; Erdmann, G; Sachse, C; Templin, M; Hoffmann, J; Boerries, M; Schäfer, R; Regenbrecht, CRA.
Heterogeneous pathway activation and drug response modelled in colorectal-tumor-derived 3D cultures.
PLoS Genet. 2019; 15(3):e1008076-e1008076 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Haybäck Johannes
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 7
| | | | | | |
Abstract:
Organoid cultures derived from colorectal cancer (CRC) samples are increasingly used as preclinical models for studying tumor biology and the effects of targeted therapies under conditions capturing in vitro the genetic make-up of heterogeneous and even individual neoplasms. While 3D cultures are initiated from surgical specimens comprising multiple cell populations, the impact of tumor heterogeneity on drug effects in organoid cultures has not been addressed systematically. Here we have used a cohort of well-characterized CRC organoids to study the influence of tumor heterogeneity on the activity of the KRAS/MAPK-signaling pathway and the consequences of treatment by inhibitors targeting EGFR and downstream effectors. MAPK signaling, analyzed by targeted proteomics, shows unexpected heterogeneity irrespective of RAS mutations and is associated with variable responses to EGFR inhibition. In addition, we obtained evidence for intratumoral heterogeneity in drug response among parallel "sibling" 3D cultures established from a single KRAS-mutant CRC. Our results imply that separate testing of drug effects in multiple subpopulations may help to elucidate molecular correlates of tumor heterogeneity and to improve therapy response prediction in patients.

© Med Uni Graz Impressum